Hemotune Secures CHF 14 Million for Clinical Trials

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Di, Mrz 26. 2024

Hemotune’s innovative blood purification platform, HemoSystem, propels into clinical trials with a CHF 14 million Series B2 boost.

Hemotune AG, a Swiss biotech compmany, has concluded its Series B2 funding round, raising CHF 14 million, they claim in a press release. This pivotal financial injection, spearheaded by Belmondo and supported by stalwarts such as VP Venture Partners, heralds in the next stage of clinical trials for its groundbreaking HemoSystem blood purification platform.

The HemoSystem, uses nanoengineered magnetic beads. By eliminating large biomolecules directly from the bloodstream, it offers a novel avenue for multi-target treatments unattainable through conventional drug therapies.

Initially targeting the formidable challenge of sepsis-related immune suppression—a condition responsible for approximately 11 million fatalities annually and imposing a significant economic strain.

Lukas Langenegger, CEO and co-founder of Hemotune AG, expressed profound pride in the team’s milestone achievement of preclinical development and clinical trials.

Dr. Darius Madjdpour, the visionary founder at Belmondo, lauded Hemotune’s stellar performance over the past seven years, culminating in a platform technology with unparalleled potential in the medical field.

The HemoSystem’s capacity to address a spectrum of diseases and enable novel therapies was a key motivator for Belmondo’s lead role in this funding round.

Pascal Winnen, CEO of HEMEX, reaffirmed the CRO’s dedication to supporting Hemotune’s novel strategy to combat septic shock, recognising the technology’s vast potential to filter detrimental agents from the bloodstream selectively.

Verwandte Geschichten

Logitech May Increase Dividends

15 Mai 2024

Logitech to boost its dividend to CHF 1.16 per share for 2023/24, reflecting robust financial health and shareholder...

Vetropack Layoffs: Employees Demand Compensation

16 Mai 2024

Amid planned layoffs, Vetropack employees push for a social plan and the preservation of jobs at the Saint-Prex site....

Council of States: Cutting Asylum Credits

16 Mai 2024

Swiss Council of States committee recommends slashing the Federal Council's proposed funding for asylum centres by CHF...

Foreign Minister Cassis Meets With The European Council

14 Mai 2024

At the Council of Europe's meeting in Strasbourg, discussions will center on Ukraine support and AI regulation, marking...

Swiss Running Shoe Brand On: Record Breaking Quarter

14 Mai 2024

On Running's turnover exceeds CHF 500 million in Q1 2024, with sales up 21% and net profit more than doubling. Positive...

Swiss Insurance Helvetia Restructuring

16 Mai 2024

Helvetia Insurance adapts its executive management and structure to boost international operations and innovation, with...

Swiss Re Exceeds Expectations with Strong Q1

16 Mai 2024

Swiss Re kicks off 2024 with impressive Q1 earnings of $1.09 billion, outpacing estimates thanks to a strong investment...

In Kontakt bleiben

Erwähnenswert

Brian Keller Pre-Trail Detention Approved In Zurich

Erwähnenswert

6 Mai 2024

Brian Keller Pre-Trail Detention Approved In Zurich

The Swiss National Council Want To Deport Violent Eritrean’s

Erwähnenswert

27. April 2024

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Hemotune sichert sich CHF 14 Millionen für klinische Studien

Verwandte Geschichten

In Kontakt bleiben

Erwähnenswert

Brian Keller Pre-Trail Detention Approved In Zurich

Der Schweizer Nationalrat will gewalttätige Eritreer ausweisen

Schnelle Links